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A B S T R A C T
Objective: To determine whether antiepileptic drugs constitute in themselves an independent risk factor
for suicidality in patients with epilepsy.
Methods: One hundred and thirty one patients with epilepsy were recruited and followed-up during 5
years. A detailed medical history, neurological examination, EEGs, Mini-International Neuropsychiatric
Interview, executive function, and MRI were assessed. Systematically collected data were used to assess
suicidality. Multiple regression analysis was carried out to examine predictive associations between
clinical variables, psychiatric disorders, antiepileptic drugs and suicidality.
Results: We identiﬁed two AEDs related with suicide attempts (PHB and LTG) and four with suicidal risk:
PHB, PRM, PHT and LTG, but the increased of risk diminished or disappeared when psychiatric
comorbidity and other well established risk factors for suicidality were analyzed. We found a signiﬁcant
proportion of patients with depressive episodes associated with Topiramate, Phenitoin, Phenobarbital
and Lamotrigine.
Conclusion: Antiepileptic drugs probably do not have an impact on suicidality.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
journal homepage: www.e lsev ier .com/ locate /yse iz1. Introduction
On January 31, 2008, the US Food and Drug Administration
(FDA) issued an alert that a meta-analysis had found a statistically
signiﬁcant 1.80-fold increased risk for suicidality associated with
all antiepileptic drugs (AEDs).1 Various potential problems with
the meta-analysis have been identiﬁed: ﬁrst of all, adverse event
data were used rather than systematically collected data, secondly,
each of the 11 drugs, grouped together as a single class of AEDs, has
different mechanisms of action and different relative risks, some of
which were not statistically signiﬁcant and several were smaller
than one, suggesting that these drugs should not be grouped in a
single class for this purpose, thirdly, the risk of adverse effects from
uncontrolled seizures, almost certainly, outweighs the risk of
suicidality.2–8 This is very important taking into account that AEDs
are not the only option for the treatment of psychiatric disorders or
pain, but currently there is no alternative pharmacological* Corresponding author. Tel.: +53 8345541.
E-mail addresses: rene@inn.sld.cu (R.A. Machado), arletygacia@infomed.sld.cu
(A.G. Espinosa), dalivan@alumni.uchicago.edu (D. Melendrez).
1 Tel.: +53 6468331.
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.12.010treatment for epilepsy. Therefore, assessment of the risk–beneﬁt
balance for the treatment of epilepsy may be more important than
for disorders for which there are alternative treatments and AEDs
are prescribed. Although the issue of suicidality with AEDs is
controversial; the adverse effects of failing to control epilepsy are
not.9–13 Considering that serial systematic data collection of
suicidality is the only way to eliminate the biases already
discussed, we conducted the present prospective study using
validated instruments. We expect that the information collected in
the current study will help us determine the validity of the FDA
alert.
2. Methods
We conducted a prospective cohort study including 131
patients with epileptic seizures when diagnosed was ﬁrst
established in epilepsy section of our hospital.
The inclusion criteria for epilepsy were based on the ILAE
classiﬁcation,14 and all patients were followed in our unit for at
least 5 years. Exclusion criteria included clinical illnesses other
than epilepsy (cerebro-vascular accident, brain tumor, asthma,
severe coronary disease, Migraine, Multiple Sclerosis, Myasthenia
Gravis, mental retardation, Mild Cognitive Impairment, Dementiavier Ltd. All rights reserved.
R.A. Machado et al. / Seizure 20 (2011) 280–284 281and Parkinson disease) and antihistamine or alcohol consumption
within 72 h prior to the psychiatric evaluation.
2.1. Subjects
After giving informed consent, the patients were assigned to
non-aleatorized treatment with AED according to the speciﬁc
epileptic syndrome and seizure response. All patients were
followed in the outpatient clinic of a tertiary center (Epilepsy
Section, Institute of Neurology, Havana, Cuba), fromMarch 2004 to
December 2009. The description of the epileptic syndromes and
the subjects who participated in the present study appear in Table
1. Thirty-one patients were excluded: 9 because they did not
complete the follow-up scheme, 16 because a secondary cause for
epilepsy was diagnosed (9 patients had a cerebrovascular event, 7
patients had brain tumor), the remaining 6 patients refused to
participate and to answer the questionnaires. All patients are
evaluated with electroencephalogram and Magnetic Resonance
Imaging (MRI).
2.2. Procedures
2.2.1. Neurological investigation
The neurological evaluation was conducted at baseline and
during follow-up (every 3 months). The neurological investigation
consisted of a detailed medical history, neurological examination
and serials electroencephalogram (EEGs) andMRI. When temporal
lobe epilepsywas suspectedwe estimate left or right epileptogenic
zone taking into account clinical, neuropsychological, EEG, and
MRI features. At a minimum, clinicians obtained the following
clinical data: (1) current or past history of the main depressive and
anxiety disorders (e.g., major depressive disorder, generalized
anxiety disorder, panic disorder); (2) current or past history of
suicidal attempts both during the interictal and postictal periods;
and (3) family psychiatric history of mood disorders and suicidal
behavior. When we identiﬁed current psychiatric symptoms or
suicidality, we referred the patient to a mental health care
professional for treatment.
2.2.2. Psychiatric evaluation
We recorded clinical and sociodemographic data such as years
of education, marital status, economic difﬁculties, labor market
status, annual income, absences fromwork due to illness, aswell as
personality disorders. The same psychiatrists (S.G.B. and A.G.E.)
evaluated each subject during enrolment in the study (at baseline)
using a structured interview (Mini-International Neuropsychiatric
Interview [MINI]),15 and conducted the follow-up looking forTable 1
Demographic characteristics in patients with epilepsy.
Epileptic syndrome n=131
Temporal lobe epilepsy 101 (77.1)
Juvenile myoclonic epilepsy 24 (18.3)
Cryptogenic frontal lobe epilepsy 4 (3.1)
Cryptogenic parietal lobe epilepsy 2 (1.5)
Gender females/males n (%) 71/60 (54.2/45.8)
Age (years) Mean SD 41. 414,3 (range: 18–78)
Age at onset of epilepsy (years) Mean SD 24.916.9 (range: 6.5–55)
Disease duration (years) Mean SD 19.713.6 (range: 1–33)
Localization of epileptiform discharges
Restricted to temporal lobe 80 (61.1)
No epileptiform discharges 21 (16.3)
Generalized epileptiform discharges 24 (18.3)
Fronto-parietal discharges 6 (4.5)
Average full scale IQ Mean SD 93.57.5 (range: 87–99)
Education
High school and/or university 126 (96.2)
<High school 5 (3.8)psychiatric complications or suicide attempts. The mood and
anxiety disordermodules of theMINIwere used to identify current
and past rates of depression and anxiety. The mood disorders
module of the structured clinical interview for DSM-IV-R Axis I
Disorders—Research Version (SCID-I) was used also to obtain data
on past major depressive episodes.[16]
After initial evaluation the psychiatrists established suicidal
risk, and current and past depressive disorder for every patient
according to the suicidal risk scale, MINI and SCID-I. For this study,
full scale SR scores greater than 7 indicated suicidal risk.
For the purposes of this study, suicidal risk (SR), depressive
disorder and other psychiatric complications were assessed with
the appropriate module of the MINI also every 3 months or when
patients referred symptoms suggesting psychiatric complications.
2.2.2.1. Evaluation of psychiatric conditions in the relatives. When
family history of psychiatric conditions was reported we asked the
patients to bring an appropriate certiﬁcate signed by her or his
psychiatrist. Only information about ﬁrst and second degree
relatives was accepted.
2.2.3. Neuropsychological evaluation
Each subject received a comprehensive neuropsychological
assessment using neuropsychological instruments previously
validated in Cuba by M.E.G.
2.3. Statistical analysis
Logistic regression was used to examine whether AEDs affected
suicidal risk, suicide attempts and depressive episodes. For these
purposes, we associated AEDs regiment of treatment with
psychiatric complication only if AEDs had been used for at least
a week. To determine the relationship between suicidal risk,
suicide attempts, depressive disorders and treatment with AED,
the psychiatric complications (depressive disorders and suicide
attempts) should be documented during the follow-up and should
not be present at baseline or the suicidal risk scale score increased
over baseline score during treatment. We considered suicidal risk
in patients scoring over 7 points on the suicidal risk scale.
A secondanalysiswasperformedexcluding thepossible inﬂuence
of psychiatric disorders on suicidal risk and suicide attempts. For this
purpose we conducted a logit regression for categorical (binary)
dependent variables (depressive disorders, suicidal risk, and suicide
attempts) and a list of predictor variables (AEDs). We used the
generalized linear models to perform stepwise and best subset
selection of predictors in ANCOVA-like designs. This statistical
analysis reports also the covariance matrix of parameter estimates
and classiﬁcation odds ratios. To carry out this type of analysis
depressive disorders, suicidal risk and suicide attempts were
analyzed as dependent variables and each AED as an independent
variable, whereas the following covariates were controlled: uncon-
trolled seizures, psychiatric co morbidity and past history of suicidal
behavior or psychiatric disorders were controlled.
We considered both ‘‘current episode of psychiatric disorders’’
and ‘‘previous history of psychiatric episodes’’ when documented
in the clinical records. Multiple regression analysis was conducted
to examine the role of AEDs on suicide attempts when other risk
factors for suicide in patients with epilepsy were present, such as
executive dysfunction, gender, depressive disorder, familiar
history of psychiatric diseases, disease duration, left temporal
lobe epilepsy, and postictal psychosis
3. Results
Patients’ demographic and clinical characteristics appear in
Table 1.
Table 2
Monotherapy regimen of treatment in our series.
Antiepileptic drugs N (%) Range of doses
Phenobarbital (PHB) 15 (11.5) 3–5mg/Kg/daily
Phenytoin (PHT) 15 (11.5) 3–8mg/Kg/daily
Carbamazepine (CBZ) 38 (29) 10–30mg/Kg/daily
Valproate (VPA) 25 (19.1) 23–60mg/Kg/daily
Lamotrigine (LTG) 14 (10.7) 0.8–7.2mg/Kg/daily
Topiramate (TPM) 12 (9.2) 3–6mg/Kg/daily
Primidone (PRM) 12 (9.2) 5–7.8mg/Kg/daily
Table 3
Suicidal risk and suicide attempts in our patients during enrollment and follow up.
Suicidal risk and suicide attempts in the study n (%)
Suicidal thoughts 70 (53.4)
Suicide attempts before epilepsy diagnosedz 4 (3.1)
Suicide attempts after diagnosis of epilepsy 38 (32.8)
Suicidal risk initially (with at least a week under treatment) 48 (36.6)
Suicidal risk when psychiatric complication emerged 68 (60.1)
 All of them have experienced depressive episodes.
Table 5
Suicidal risk and suicide attempts according to antiepileptic drugs when personal
and family history of psychiatric disorders were statistically controlled variables.
Medication OR (CI)
Phenobarbital (PHB) 0.9 (0.1–5.9)
Phenytoin (PHT) 1.2 (0.5–1.9)
Carbamazepine (CBZ) 0.1 (0.1–1.2)
Valproate (VPA) 0.5 (0.1–0.6)
Lamotrigine (LTG) 0.5 (0.7–1.9)
Topiramate (TPM) 2.9 (0.9–3.2)
Primidone (PRM) 1.1 (0.8–4.9)
Table 6
Contribution of each factor affecting the risk for suicide and suicide attempts in
patients with epilepsy taking antiepileptic drugs.
Factors affecting the risk for
suicide and suicide attempts
Suicide
attempts OR (IC)
Suicidal
risk OR (IC)
Depression (current episode) 3.3 (1.1–46.1)* 3.4 (1.9–23.4)***
Recurrent depressive disorder 6.7 (2–41.1)* 7.9 (2.1–29.6)***
Familiar history of psychiatric
disorders
1.8 (1.2–3.6) 2.1 (1.9–4.5)**
Executive dysfunction 4.8 (1.5–15.2)* 5.6(2.8–7.9)**
Gender (female) 0.5 (0.8–2.4) 0.9 (0.2–0.7)
Disease duration 0.9 (1.7–2.2)* 0.3 (1.01–3.7)*
Perictal psychosis 2.1 (2.1–8.7)* 2,4 (3.2–9.7)**
Examination for suicide attempts (logistic regression): OR 2.2 IC (1.1–3.7) Chi2
(11) =37.6 p=0.0000. Assessment for suicidal risk (logistic regression): OR 1.8 IC
(1.3–3.4) Chi2 (11) =41.3 p=0.0000.
* Mean p0.05 but >0.01.
** p=0.01.
*** p<0.01.
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Antiepileptic drugs and their respective dosages are shown in
Table 2. Old and new antiepileptic drugs were used.
3.2. Risk for suicide and suicide attempts in our series (Table 3)
Forty eight of 131 individuals (36.6%) scored >7 on the SR
module of MINI when they were enrolled in the study and after at
least one week under treatment, but this number of patients
increased up to 68 (60.1%) when psychiatric complications
emerged. Thirty-eight patients (32.8%) had attempted suicide
during the follow-up; nevertheless, 4 of 131 patients (3.1%) had at
least one suicide attempt before epilepsy was diagnosed, hence
they had not received antiepileptic treatment yet (all of them had
experienced depressive episodes). No information was available
regarding the severity of these suicide attempts. More than ﬁfty
percent of patients experienced suicidal thoughts (53.4%).
3.2.1. Suicide attempts, suicidal risk and depressive disorder
according to antiepileptic drug on monotherapy regimen of treatment
(Table 4)
The patients in the table represent patientswith new symptoms
(n = 20) and who developed worsening symptoms (n = 28). The
number of patients with suicidal risk was greater for patients
treated with PRM (primidone), LTG (Lamotrigine), PHB (pheno-
barbital) and Phenitoin (PHT). Suicide attempts were reported in 5
of 15 patients treated with PHB (33.3%), 5 of 15 patients treated
with PHT (33.3%), 8 of 14 individuals treated with LTG (57.1%). The
probability of suicide attemptswas greater in patients treatedwithTable 4
Suicide attempts, suicidal risk and depressive disorder according to antiepileptic drug
AED Depressive disorder Suicidal risk
OR (CI) Yes (%) No (%) OR (CI)
PHB 1.3 (1.1–1.9) 5 (33.3) 10 (66.7) 1.9 (1.1–2.9)
PHT 2.1(1.2–4.3) 3 (20) 12 (80) 1.9 (1.1–2.9)
CBZ 1.3 (0–12) 7 (18.4) 31 (81.6) 2 (0–14)
VPA 0.4 (0.2–2.5) 6 (24) 19 (76) 2.3 (0.8–5)
LTG 0.2 (0.3–7.3) 4 (28.6) 10 (71.4) 7.2 (2.3–14.3)
TPM 1.5 (1.2–2.3) 4 (33.3) 8 (67.7) 1.5 (1–3.4)
PRM 2.9 (2.1–1.9) 4 (33.3) 8 (67.7) 1.9 (1.2–2.1)
% are referred to total patients with each drug on monotherapy regimen. The following
history of suicidal behavior or psychiatric disorders were controlled. The patients in the t
symptoms (n=28).PHB (OR 1.2; CI (2.3–3.4) and LTG (OR 6.2; CI (2–7.8)). Patients who
were under treatment with the following AEDs (PHB, PHT, TPM)
had an increased probability to develop depressive episodes
[OR > 1 and valid CI].
3.2.2. The effect of AEDs on suicidality when comorbidity of epilepsy
with depressive disorders was statistically controlled (Table 5)
When variables such as family history of depressive disorders
and current depressive episodes were controlled the regression
model did not show statistically signiﬁcant differences by
subgroup of antiepileptic drugs analyzed (i.e., OR < 1 or 95%
CI = 1).
3.3. Risk factors for suicide attempts and suicidal risk in our series: the
contribution of antiepileptic drugs when others risk factors are present
(Table 6) (multivariate analysis)
The overall regression model explained the signiﬁcant propor-
tion of variance for both suicide risk and suicide attempts. There
was a 1.8-fold increase in the risk for suicide in those with a familyon monotherapy regimen of treatment.
Suicide attempts
Yes (%) No (%) OR (CI) Yes (%) No (%)
7 (46.6) 8 (53.4) 1.2 (2.3–3.4) 5 (33.3) 10 (66.7)
7 (46.6) 8 (53.4) 1.2 (2.3–3.4) 5 (33.3) 10 (66.7)
9 (23.7) 29 (76.3) 3 (0–26) 9 (23.7) 29 (76.3)
8 (32) 17 (68) 6.2 (1–7) 8 (32) 17 (50)
7 (50) 7 (50) 6.2 (2–7.8) 8 (57.1) 6 (42.9)
4 (33.3) 8 (67.7) 3.1 (2–3.9) 1 (8.3) 11 (91.7)
6 (50) 6 (50) 1.4 (1.3–1.5) 2 (16.6) 10 (83.3)
covariates were controlled uncontrolled seizures, psychiatric comorbidity and past
able represent patients with new symptoms (n=20) and who developed worsening
R.A. Machado et al. / Seizure 20 (2011) 280–284 283history of psychiatric disease, longer disease duration, current and
past history depressive episode, executive dysfunction, perictal
psychosis and female gender [95% IC (1.3–3.4) Chi2 (11) = 41.3
p = 0.0000]. Themodel also explained a 2.2-fold increase in the risk
for suicide attempts [OR 2.2 IC (1.9–3.9) Chi2 (11) = 37.6
p = 0.0000]. AEDs were not associated with an increase of the
suicidal risk or suicide attempts.
4. Discussion
The analysis of suicidality in the present sample could be biased
due to the excessive representation of patients predisposed
biologically to suicide such as patients with temporal lobe
epilepsy,16–33 but it adequately represented the population of
people with epilepsy in our clinical setting. We did not include
patients with other secondary causes for epilepsy (i.e., cerebro-
vascular accident, tumors, vascularmalformations, central nervous
system infection and trauma) to avoid an even more complicated
analysis of the complex relationship among epilepsy, AEDs and
suicidality.
In the present study, the data concerning rate of suicidal risk
and suicide attempts were registered systematically. For this
purpose we used the standardized MINI. We also analyzed each
AED separately; the effects from uncontrolled seizures, psychiatric
comorbidity and past history of suicidal behavior or psychiatric
disorders were controlled. The use of systematically collected data,
rather than adverse event data on suicidality, is one of the
strengths of our study for several reasons. Systematically collected
data is obtained from reports of the event at hand using a validated
scale (MINI in our study). The use of a validated scale limited the
number of patients reportingmore adverse eventswhen compared
to patients taking a placebo,3,4 and thus, we avoided the
phenomenon referred to as reporting bias. The FDA accepts
systematically collected data as the primary endpoint in a clinical
trial.
We identiﬁed two AEDs related with suicide attempts (PHB and
LTG) and four AEDs related with suicidal risk (PHB, PRM, TPM and
LTG), but such risk diminished or disappeared as psychiatric
comorbidity and other well established risk factors for suicidality
were statistically controlled. These results suggest that personal or
familiar history of psychiatric disorders and/or current depressive
episodes play a pivotal role in suicidal behavior in patients with
epilepsy. The relevant message is that previous psychiatric history
and family psychiatric history are the major determinants for the
development of suicidal ideation and suicidal attempts rather than
the AED.
The incidence of psychiatric disorders in patients taking AEDs as
previously reported26,33–36 was veriﬁed in our study. A subgroup of
patients who were under treatment with PHB, PHT, LTG and TPM
displayed an increased susceptibility to develop depressive
episodes [OR > 1 and valid CI]. The previous studies could not
rule out the contribution of other factors such as family history of
psychiatric disorders or past psychiatric disorders as we were able
to do.1,31,32 We mention these studies because psychiatric
disorders, which can potentially facilitate the development of
suicidal attempts and increase the suicidal risk, have been
associated with PHB and PRM (among the older AEDs), and with
vigabatrin, levetiracetam, TPM, and zonisamide (among second-
generation AEDs).33,34 Still, the incidence of suicidal behavior
resulting from AED exposure itself remains unknown, as most
published data group all psychiatric adverse events together,33,34
rather than reporting suicidality by itself, and those studies
reporting suicidality have not adjusted for prior episodes of
depression and prior suicidality.1,31–33 In the present study, we
independently investigated depressive disorder and other psychi-
atric complications in patients with epilepsy and adjusted for anincrease of suicidality for AEDs and for previous depressive
episodes. Only four out of 131 patients reported attempting suicide
before being treated with AEDs; all of them had previously
experienced depressive episodes.
4.1.1. ADEs and psychiatric comorbidity in patients with epilepsy
Our results mirror other case studies of patients treated with
AEDs. Trimble et al.33 investigated psychiatric adverse events in
patients with epilepsy taking AEDs and found that nearly two-
thirds of the patients had a psychiatric history with a strong
association between the type of past psychiatric illness and the
emerging illness. In studies conducted with patients treated with
Levetiracetam, a family history of psychiatric disorders was a
signiﬁcant predictor for the development of psychiatric symp-
toms.35,36 Among patients treated with Topiramate, 23% were
found to exhibit psychiatric symptoms. The risk was greater in
patients with a family psychiatric history and in those with a
previous psychiatric history.33,34 Therefore, a family history of
psychiatric disorders is associated with an increased risk to
develop psychiatric disorders, predominantly depression, while
taking AEDs. This may reﬂect the natural course of an underlying
recurrent psychiatric illness with no effects from AEDs, or it could
suggest that AEDs lower the threshold for manifesting psychiatric
symptoms in individualswho are vulnerable because of a history of
psychiatric disorders.
Considering the logistic regression model, suicide risk and
suicide attempts were higher than the individual risks for each
variable, suggesting that these factors share a common pathogenic
mechanism in suicide risk.
The association found among family history of psychiatric
diseases, current depressive episode, duration of epileptic diseases,
perictal psychosis, executive dysfunction, gender, suicide
attempts, and suicide risk in patients with epilepsy strengthens
the idea of the existence of a biological basis underlying epilepsy
and suicidal risk.In conclusion, the relationship between suicid-
ality and epilepsy is a complex, multifactorial issue, and AEDs
probably have little or no impact. Serial systematic data collection
of suicidality did not suggest that AEDs play an important role in
suicidality.
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